MattWachsmanMD

Journal Articles

• A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs  
  Wachsman M, Kulka M, Smith CC, Aurelian L., Vaccine, 1/28/2001
• Direct Measurement of unfractionated Heparin in man using a biochemical assay  
  Mielke, CH., C.M. Starr, J.C. Klock, D. Devereaux, M.R. Mielke, D.E. Baker, L. Broemeling, M. Wachsman, et al., Clinical Appl. Hemostasis., 1/1/1999
• Lack of beta-oxidation defects in HIV+ subjects with and without chronic zidovudine exposure  
  Wachsman, M., P. Barditch-Crovo, C.P. Trapnell, S.W. Brusilow, and P.S. Lietman, Blood, 1/1/1996
• Specific Anti-cytomegaloviral activity of methotrexate  
  Wachsman, M., H. Saito, F. M. Hamzeh, and P. S. Lietman., Antimicrob. Agents and Chemo., 1/1/1996
• Antiviral activity of inhibitors of pyrimidine de novo biosyn�thesis  
  Wachsman, M., F. M. Hamzeh, N. Badie, and P.S. Lietman., Antivir. Chem. and Chemo, 1/1/1996
• Pharmacokinet�ics, Safety and Bioavaila�bility of HPMPC (Cidofovir) in HIV-infect�ed Subjects  
  Wachsman, M., B. G. Petty, K. C. Cundy, H. S. Jaffe, P. E. Fishe�r, A. Pastelak, and P.S. Lietman., Antiviral Res., 1/1/1996
• Clinical pharmacokinetics of Cidofovir in HIV-1 infected subjects  
  Cundy, K.C. H. S. Jaffe, P. E. Fisher, Wachsman, M. and B. G. Petty., Antimicrobial Agents and Chemo�therapy, 1/1/1995
• The effect of systemically administered recombinant human nerve growth factor in healthy human sub�jects  
  Petty, B.P., D.R. Cornblath, B.T. Adornato, V. Chaundhry, C. Flexner, M. Wachsman, D. Sinicropi, L.E. Burton, and S.J. Peroutka., Annals of Neurol., 1/1/1994
• Antiviral effect of oligo(nucleoside methylphosphonates) complimentary to the herpes simplex virus type 1 immediate early mRNA's 4 and 5  
  Kulka, M., M. Wachsman, S. Miura, R. Fishelevich, P.S. Miller, P.O.P. T'so, and L. Aurelian., Antiviral Res., 1/1/1993
• Protection from HSV-2 cutaneous disease by vaccinia recombinants express�ing glycoprotein D correlates with induction of DTH  
  Wachsman, M., L. Aurelian, and E. Paoletti., Vaccine, 1/1/1992
• Immune responses to herpes simplex virus in guinea pigs (foot�pad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprote...  
  Aurelian, L., C.C. Smith, M. Wachsman, and E. Paoletti., Rev. Inf. Dis, 1/1/1991
• Human immunosuppression induced by sea nettle (Chrysoara quinquecir�rha) venom  
  Wachsman, M., J. Burnett, and L. Aurelian., Toxicon, 1/1/1991
• Clinical and subclinical HSV infection resulting from exposure to asymptomatic patients  
  Aurelian L. M. Wachsman M. and J.W. Burnett., Br J Dermatol., 1/1/1990
• The prophy�lactic use of cyclooxyge�nase inhibitors in recurrent herpes simplex infections  
  Wachsman, M., L. Aurelian, and J.W. Burnett, Brit. J. Derm, 1/1/1990
• Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants contain�ing the herpes simplex virus glycoprotein D and protective immunity  
  Wachsman, M., J.H. Luo, L. Aurelian, M.E. Perkus, and E. Paoletti., J. Gen. Virol, 1/1/1989
• Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease  
  Wachsman, M., L. Aurelian, M.E. Perkus, and E. Paoletti., J. Inf. Dis, 1/1/1988
• Expression of herpes simplex virus glyco�pro�tein D in antigen presenting cells infected with vaccinia recombinants and protective immunity  
  Wachsman, M., L. Aurelian, J.C.R. Hunter, M.E. Perkus, and E. Paoletti, Biosci. Reports, 1/1/1988
• Protection of guinea pigs from pri�mary and recurrent herpes simplex virus type 2 cutane�ous disease with vaccinia virus recombinants ex�pressing HSV glyco�protein D  
  Wachsman, M., L. Aurelian, C.C. Smith, B.R. Lipinskas, M.E. Perkus, and E. Paoletti., J. Inf. Dis., 1/1/1987
• Aug�mentation of natural immune defence mechan�isms and therapeutic potential of a mis�matched double-stranded polynu�cleotide in cutaneous herpes simplex virus type 2...  
  Aurelian, L., C. Rinehart, M. Wachsman, M. Kulka, and P.O.P. Ts'O., J. Gen. Virol, 1/1/1987
• Join now to see all

Abstracts/Posters

• Mathematically modeling attrition from buprenorphine/naloxone treatment—finding the lost
  Matt Wachsman MD PhD, AAAP meeting, Bonita Springs, FLA, 12/8/2018
• Mathematically modeling attrition from buprenorphine/naloxone treatment�finding the lost.
  M Wachsman., AAAP meeting, 1/1/2018
• A new pathogenic target for pain control using an old drug�acetazolamide for joint pain of damp weather.
  M Wachsman and I.L. Wachsman, Southern Medical Journal Conference, 1/1/1999
• Use of time step simulations and difference equations (tssadeq) in drug development.
  M Wachsman, and J. A. Hayes, Am Coll Clin Pharm Meeting, Phoenix, 1/18/1997
• Subclinical Markers of Mitochondrial Toxicity from Nucleoside Analogs: From Benchtop to Clinic
  Wachsman, M., P. Barditch-Crovo, C.B. Trapnell, S. Brusilow, and P.S. Lietman, PhRMA Foundation Awardee�s Meeting, Washington D.C., 1/1/1997
• Optimal Trial Design: modeling the intracellular metabolism of zidovudine.
  Wachsman, M., and J.A. Hayes., PhRMA Foundation Awardee�s Meeting, Washington D.C., 1/1/1997
• Subclinical Markers of Mitochondrial Toxicity from Nucleoside Analogs: From Benchtop to Clinic.
  Wachsman, M., P. Barditch-Crovo, C.B. Trapnell, S. Brusilow, and P.S. Lietman., PhRMA Foundation Awardee�s Meeting, Washington D.C., 1/18/1996
• Screening for beta-oxidation abnormalities as an indicator of drug-induced impaired mitochondrial function in people receiving zidovudine.
  Wachsman, M, P Barditch-Crovo BG Petty, CB Trapnell, S Brusilow, , PS Lietman, ASCPT, Orlando FL, 1/1/1996
• Spe�cific Anti-Cytomegaloviral Activity of Methotrexate Associ�ated with Preferential Accumulation of Drug by Infected Cells.
  Wachsman, M., F.M. Hamzeh, H. Saito, and P. S. Lietman., Antiviral Res, 1/1/1995
• Phase I trial of a new anti-cytomegalo�virus agent, (S)-1[3-hydroxy-2-(phosphonyl-methoxy)propyl]�cytosine (HPMPC), in HIV-infected volunteers.
  Wachsman, M., B.G. Petty, H.S. Jaffe, K. Cundy, P. Fisher and P.S. Lietman., Antiviral Res., 1/1/1994
• Increased suscepti�bility to infectious agents following in vivo lipopolysaccharide administration.
  Metcalf, E.S., M. Wachsman, L. Aurelian, and E.A. Goidl, FASEB, 1/1/1988
• The effect of temporal regulation of HSV gD expression in vaccinia recom�binants on protective immunity.
  Wachsman, M., L. Aurelian, E. Paoletti., Am. Soc. Virol., Austin. TX., 1/1/1988
• Vaccinia recombinant expressing glycoprotein D does not prime for HSV-2 induced immunosuppres�sion.
  Wachsman, M., L. Aurelian, and E. Paoletti., 12th Internation�al Herpesvirus Workshop., Philadelphia, PA, 1/1/1987
• Protection from lethal and recurrent cutaneous HSV-2 disease by vaccinia recombinants expressing glycoprotein D.
  Wachsman, M., K. Hepper, L. Aurelian, and E. Paoletti, 11th international Herpes�virus Workshop, Leeds, U.K., 1/1/1986
• Sequen�tial ascending multiple-dose safety and pharmacokin�etic study of oral lobucavir (BMS-18-194) in asymptomatic volunteers seropositive for HIV and CMV.
  Petty, B.G., M. Wachsman, M.C. Jordan, H. Burgee, D. DeHer�togh, D. Collins, R.S. Summerill, D.A. Jabs, et. al., Antiviral Res
• A random�ized, double-blind, placebo-controlled phase I/II evaluation of 9-[2-(bispivaloyloxy-methyl)phosphonyl-methoxy]adenine (bis-POM PMEA), an orally bioavailable ...
  Barditch-Crovo, P.A., J. Toole, H. Burgee, M. Wachsman, D. Ebeling, K.C. Cundy, H.S. Jaffe, and P.S. Lietman., Antiviral Res
• Join now to see all

Other

• Focus: Famciclovir. 
  Wachsman, M, Formulary Magazine
  1/1/1995